References:
- Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J,
et al. An individual patient meta-analysis of five randomized trials
assessing the effects of cardiac resynchronization therapy on
morbidity and mortality in patients with symptomatic heart failure.
Eur Heart J. 2013;34:3547–3556. doi: 10.1093/eurheartj/eht290
- Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al;
MADIT-CRT Investigators. Effectiveness of cardiac resynchronization
therapy by QRS Morphology in the Multicenter Automatic Defibrillator
Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).
Circulation. 2011;123:1061–1072. doi: 10.1161/
CIRCULATIONAHA.110.960898.
- Normand C, Linde C, Singh J, Dickstein K. Indications for cardiac
resynchronization therapy: a comparison of the major international
guidelines. JACC Heart Fail 2018;6:308–316.
- Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L,
Shinn T, Sutton MS; Biventricular versus Right Ventricular Pacing in
Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial
Investigators. Biventricular pacing for atrioventricular block and
systolic dysfunction. N Engl J Med 2013;368:1585–1593.
- Vamos M, Erath JW, Bari Z, Vagany D, Linzbach SP, Burmistrava T,
Israel CW, Duray GZ, Hohnloser SH (2017). Effects of upgrade versus de
novo cardiac resynchronization therapy on clinical response and
long-term survival: results from a multicenter study. Circ Arrhythmia
Electrophysiol 10(2):e004471.
https://doi.org/10.1161/circep.116.004471
- Cheung JW, Ip JE, Markowitz SM, Liu CF, Thomas G, Feldman DN, et al.
Trends and outcomes of cardiac resynchronization therapy upgrade
procedures: a comparative analysis using a United States National
Database 2003-2013. Heart Rhythm (2017), doi:
10.1016/j.hrthm.2017.02.017.
- Martinelli Filho M, Peixoto GL, Siqueira SF, Nishioka ASD, Pedrosa
ALA, Teixeira RA. A cohort study of cardiac resynchronization therapy
in patients with chronic Chagas cardiomyopathy. Europace
2018;20:1813–8.
- Passos LCS, Vieira de Melo RM, Lira YM, Oliveira NFC, Trindade TC,
Carvalho W, et al . Chagas disease is associated with a poor outcome
at 1-year follow-up after cardiac resynchronization therapy. Rev.
Assoc. Med. Bras. [Internet]. 2019 Nov [cited 2020 May
12] ; 65( 11 ): 1391-1396.
https://doi.org/10.1590/1806-9282.65.11.1391.
- St. John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB,
Leon AR, et al. Effect of cardiac resynchronization therapy on left
ventricular size and function in chronic heart failure. Circulation.
2003;107(15):1985–90.
- Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al.
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure
Events. N Engl J Med. 2009;361(14):1329–38.
- Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F, et al.
The European Cardiac Resynchronization Therapy Survey: comparison of
outcomes between de novo cardiac resynchronization therapy
implantations and upgrades. Eur J Heart Fail 2011;13:974-83.
- Kosztin A, Vamos M, Aradi D, Schwertner WR, Kovacs A, Nagy KV, et al.
De novo implantation vs. upgrade cardiac resynchronization therapy: a
systematic review and meta-analysis. Heart Fail Rev. 2018;23(1):15‐26.
doi:10.1007/s10741-017-9652-1.
- Beca B, Sapp JL, Gardner MJ, Gray C, AbdelWahab A, MacIntyre C, et al.
Mortality and Heart Failure After Upgrade to Cardiac Resynchronization
Therapy. CJC Open. 2019;1(2):93‐99. Published 2019 Mar 6.
doi:10.1016/j.cjco.2019.02.002
- Linde CM, Normand C, Bogale N, Auricchio A, Sterlinski M, Marinskis G,
et al. Upgrades from a previous device compared to de novo cardiac
resynchronization therapy in the European Society of Cardiology CRT
Survey II. Eur J Heart Fail. 2018;20(10):1457‐1468.
doi:10.1002/ejhf.1235
- Mady C, Cardoso RH, Barreto ACP, Da Luz PL, Bellotti G, Pileggi F.
Survival and predictors of survival in patients with congestive heart
failure due to Chagas’ cardiomyopathy. Circulation. 1994; 90:
3098-102.
- Silva CP, Del Carlo CH, Oliveira MT Junior, Scipioni A, Strunz-Cassaro
C, Ramirez JA, et al. Why do patients with chagasic cardiomyopathy
have worse outcomes than those with non-chagasic cardiomyopathy? Arq
Bras Cardiol. 2008;91(6):358–62.
- Oliveira-Filho J, Viana LC, Vieira-de-Melo RM, Faiçal F, Torreão JA,
Villar FA, et al.. Chagas disease is an independent risk factor for
stroke: baseline characteristics of a Chagas Disease cohort. Stroke.
2005; 36:2015–2017.